1114 related articles for article (PubMed ID: 11948130)
1. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
2. The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002.
Siwak DR; Tari AM; Lopez-Berestein G
Clin Cancer Res; 2002 Apr; 8(4):955-6. PubMed ID: 11948099
[No Abstract] [Full Text] [Related]
3. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
4. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
6. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer.
Laginha KM; Moase EH; Yu N; Huang A; Allen TM
J Drug Target; 2008 Aug; 16(7):605-10. PubMed ID: 18686132
[TBL] [Abstract][Full Text] [Related]
8. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
Nam SM; Kim HS; Ahn WS; Park YS
Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027
[TBL] [Abstract][Full Text] [Related]
9. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
13. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
15. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
17. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
18. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
Drummond DC; Marx C; Guo Z; Scott G; Noble C; Wang D; Pallavicini M; Kirpotin DB; Benz CC
Clin Cancer Res; 2005 May; 11(9):3392-401. PubMed ID: 15867240
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]